(Q46748655)

English

12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

1 reference

based on heuristic

inferred from title

attention deficit hyperactivity disorder

1 reference

based on heuristic

inferred from title

Helmut Remschmidt

2

object named as

H Remschmidt

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

Aribert Rothenberger

5

object named as

A Rothenberger

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

author name string

Peter Hoare

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

R Medori

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

C Ettrich

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

P Santosh

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

M Schmit

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

Q Spender

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

R Tamhne

9

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

M Thompson

10

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

C Tinline

11

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

G E Trott

12

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

publication date

1 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

European Child & Adolescent Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

14

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

305-309

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

https://scigraph.springernature.com/pub.10.1007/s00787-005-0486-3

0 references

Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status.

1 reference

https://api.crossref.org/works/10.1007%2FS00787-005-0486-3

21 January 2018

Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16220214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/16220214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16220214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings

1 reference

https://pubmed.ncbi.nlm.nih.gov/16220214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry

1 reference

https://pubmed.ncbi.nlm.nih.gov/16220214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/16220214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions

1 reference

https://pubmed.ncbi.nlm.nih.gov/16220214

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00787-005-0486-3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16220214

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46748655&oldid=2126769329"